Olema Pharmaceuticals (NASDAQ:OLMA) Now Covered by Analysts at Stifel Nicolaus

Equities researchers at Stifel Nicolaus began coverage on shares of Olema Pharmaceuticals (NASDAQ:OLMA) in a research note issued on Wednesday. The brokerage set a “buy” rating and a $48.00 price target on the stock. Stifel Nicolaus’ target price indicates a potential upside of 105.39% from the company’s previous close.

Other analysts also recently issued reports about the company. Oppenheimer lifted their price target on Olema Pharmaceuticals from $45.00 to $48.00 and gave the stock an “outperform” rating in a report on Thursday, December 11th. UBS Group initiated coverage on shares of Olema Pharmaceuticals in a research report on Wednesday, January 7th. They issued a “buy” rating and a $45.00 target price on the stock. The Goldman Sachs Group boosted their target price on Olema Pharmaceuticals from $26.00 to $38.00 and gave the company a “buy” rating in a report on Thursday, December 11th. HC Wainwright upped their target price on Olema Pharmaceuticals from $36.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Finally, JPMorgan Chase & Co. raised their price target on Olema Pharmaceuticals from $29.00 to $32.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 18th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.78.

Olema Pharmaceuticals Price Performance

OLMA stock opened at $23.37 on Wednesday. Olema Pharmaceuticals has a 1 year low of $2.86 and a 1 year high of $36.26. The firm has a market capitalization of $1.60 billion, a P/E ratio of -12.50 and a beta of 1.89. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.03 and a quick ratio of 8.03. The business’s 50-day moving average is $27.30 and its two-hundred day moving average is $15.91.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its earnings results on Monday, November 10th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.05). Analysts anticipate that Olema Pharmaceuticals will post -2.33 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Cyrus Harmon sold 10,000 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $26.88, for a total transaction of $268,800.00. Following the completion of the sale, the director directly owned 727,770 shares of the company’s stock, valued at $19,562,457.60. This trade represents a 1.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Shane William Charles Kovacs sold 100,000 shares of the business’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $28.73, for a total transaction of $2,873,000.00. Following the completion of the transaction, the insider directly owned 139,727 shares in the company, valued at $4,014,356.71. This represents a 41.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 765,501 shares of company stock worth $22,052,432 over the last three months. 16.36% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in OLMA. EverSource Wealth Advisors LLC lifted its position in Olema Pharmaceuticals by 9,476.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock valued at $31,000 after purchasing an additional 1,232 shares during the period. Torren Management LLC purchased a new position in shares of Olema Pharmaceuticals during the 4th quarter worth approximately $44,000. Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new position in shares of Olema Pharmaceuticals during the 4th quarter worth approximately $88,000. Nisa Investment Advisors LLC lifted its holdings in shares of Olema Pharmaceuticals by 14.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company’s stock valued at $94,000 after buying an additional 477 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Olema Pharmaceuticals by 44.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,822 shares of the company’s stock valued at $96,000 after buying an additional 1,169 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.